|DB01431||Allylestrenol||Allylestrenol was designed to be used for miscarriage prevention, prevention of premature labour and has been investigated for possible use in men for treatment for benign prostatic hyperplasia.|
|DB00294||Etonogestrel||Etonogestrel is administered in subdermal implants as long-acting reversible contraception. It is known to be effective in postpartum insertion including breastfeeding women.[A175990]
Etonogestrel is part of the long-acting contraceptive implants that prevent pregnancy. The implant's effect can remain for 5 years.[L5698]|
|DB00603||Medroxyprogesterone acetate||Used as a contraceptive and to treat secondary amenorrhea, abnormal uterine bleeding, pain associated with endometriosis, endometrial and renal cell carcinomas, paraphilia in males, GnRH-dependent forms of precocious puberty, as well as to prevent endometrial changes associated with estrogens.|
The gelatinized capsules are indicated for use in the prevention of endometrial hyperplasia in non-hysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea [FDA label].
Progesterone gel (8%) is indicated as progesterone supplementation or replacement as part of an Assisted Reproductive Technology (“ART”) treatment for infertile women with progesterone deficiency. The lower concentration progesterone gel (4%) is used in the treatment of secondary amenorrhea, with the use of the 8% concentration if there is no therapeutic response to the 4% gel [F3898].
This form is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment program for infertile women [F3901].
This drug is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer [F3907].
The tablet form of progesterone in contraceptive formulations is indicated for the prevention of pregnancy [F3904]. |
|DB00717||Norethisterone||For the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer.|
|DB06789||Hydroxyprogesterone caproate||Hydroxyprogesterone caproate is indicated for the prevention of spontaneous preterm births in singleton pregnancies in women who have previously had a spontaneous preterm birth. (1) |
|DB00304||Desogestrel||Oral desogestrel is used in combination with [ethinylestradiol] as a contraceptive agent for the prevention of pregnancy.[FDA label]
Desogestrel is part of the combined oral contraceptives that contain a mix of estrogen and progestin which inhibit ovulation.[L5698]|
|DB00378||Dydrogesterone||Used to treat irregular duration of cycles and irregular occurrence and duration of periods caused by progesterone deficiency. Also used to prevent natural abortion in patients who have a history of habitual abortions.|
|DB11619||Gestrinone||Endometriosis with or without accompanying sterility. Treatment is limited to a single course of 6 months duration per lifetime [L1699, L1700].|
|DB09124||Medrogestone||Medrogestone is indicated as adjunct to treat endometial shedding in menopausal women, to treat secondary amenorrhea, to induce menses and to treat dysfunctional uterine bleeding in adult and adolescent women.[T76]|
|DB00351||Megestrol acetate||For the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS). Also used for the palliative management of recurrent, inoperable, or metastatic breast cancer, endometrial cancer, and prostate cancer in Canada and some other countries.|
|DB00367||Levonorgestrel||For the treatment of menopausal and postmenopausal disorders and alone or in combination with other hormones as an oral contraceptive.|
|DB09123||Dienogest||Indicated for use as the treatment of endometriosis alone and as a contraceptive in combination with ethinylestradiol. |
|DB01395||Drospirenone||For the prevention of pregnancy in women who elect an oral contraceptive.|
|DB09389||Norgestrel||Norgestrel in combination with ethinyl estradiol is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.|
|DB00957||Norgestimate||For the prevention of pregnancy|
|DB06713||Norelgestromin||Norelgestromin is used for contraception and menopausal hormonal therapy. Norelgestromin may potentially be used in breast cancer treatment due to its inhibitory effect on estrone sulfatase . They convert sulfated steroid precursors to estrogen during pregnancy. |
|DB13981||Nomegestrol acetate||Not Available|
|DB00823||Ethynodiol diacetate||For the prevention of pregnancy in women who elect to use this product as a method of contraception.|
|DB04839||Cyproterone acetate||For the palliative treatment of patients with advanced prostatic carcinoma.|
|DB14678||Norethindrone enanthate||Not Available|
|DB14679||Quingestanol acetate||Not Available|